Cargando…

Efficacy of aggressive hydration with normal saline versus lactated Ringer’s solution for the prevention of post-ERCP pancreatitis in high-risk patients: a randomized controlled trial

Background and study aims  Post-ERCP pancreatitis (PEP) is a common adverse event in high-risk patients. Current intervention known to reduce the incidence and severity of PEP include pancreatic duct stent placement, nonsteroidal anti-inflammatory drugs per rectum, and intravenous (IV) fluids. We co...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Rupal, Bertran-Rodriguez, Carlos, Kumar, Ambuj, Brady, Patrick, Gomez-Esquivel, Rene, Changela, Kinesh, Niknam, Negar, Taunk, Pushpak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286764/
https://www.ncbi.nlm.nih.gov/pubmed/35845031
http://dx.doi.org/10.1055/a-1834-6568
_version_ 1784748091270758400
author Patel, Rupal
Bertran-Rodriguez, Carlos
Kumar, Ambuj
Brady, Patrick
Gomez-Esquivel, Rene
Changela, Kinesh
Niknam, Negar
Taunk, Pushpak
author_facet Patel, Rupal
Bertran-Rodriguez, Carlos
Kumar, Ambuj
Brady, Patrick
Gomez-Esquivel, Rene
Changela, Kinesh
Niknam, Negar
Taunk, Pushpak
author_sort Patel, Rupal
collection PubMed
description Background and study aims  Post-ERCP pancreatitis (PEP) is a common adverse event in high-risk patients. Current intervention known to reduce the incidence and severity of PEP include pancreatic duct stent placement, nonsteroidal anti-inflammatory drugs per rectum, and intravenous (IV) fluids. We compared aggressive normal saline (NS) vs aggressive lactated Ringer’s (LR) infusion for the prevention of PEP in high-risk patients undergoing ERCP. Patients and methods  Patients were randomized to receive either an aggressive infusion of NS or LR. The infusion was started at a rate of 3 mL/kg/hr and continued throughout the ERCP procedure. A 20 mL/kg bolus was given at the end of the procedure, then continued at a rate of 3 mL/kg/hr. Results  A total of 136 patients were included in our analysis. The incidence of PEP was 4 % (3/72 patients) in the LR group versus 11 % (7/64 patients) in the NS group resulting in a relative risk (RR) of 0.38 (95 % confidence interval [CI] 0.10 to 1.42; P  = 0.19). The relative risk reduction (RRR) was 0.62 (95 % CI –0.41 to 0.90) along with an absolute risk reduction (ARR) of 0.07 (95 % CI –0.025 to 0.17) and an number needed to treat of 15 (95 % CI –41 to 6). Conclusions  To our knowledge, this is the first study comparing aggressive IV NS to aggressive IV LR in high-risk patients. The incidence of PEP was lower in the group receiving an aggressive LR infusion (4 %) compared to NS infusion (11 %). However, the difference was not statistically significant likely due to poor accrual thereby impacting the power of the study.
format Online
Article
Text
id pubmed-9286764
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-92867642022-07-16 Efficacy of aggressive hydration with normal saline versus lactated Ringer’s solution for the prevention of post-ERCP pancreatitis in high-risk patients: a randomized controlled trial Patel, Rupal Bertran-Rodriguez, Carlos Kumar, Ambuj Brady, Patrick Gomez-Esquivel, Rene Changela, Kinesh Niknam, Negar Taunk, Pushpak Endosc Int Open Background and study aims  Post-ERCP pancreatitis (PEP) is a common adverse event in high-risk patients. Current intervention known to reduce the incidence and severity of PEP include pancreatic duct stent placement, nonsteroidal anti-inflammatory drugs per rectum, and intravenous (IV) fluids. We compared aggressive normal saline (NS) vs aggressive lactated Ringer’s (LR) infusion for the prevention of PEP in high-risk patients undergoing ERCP. Patients and methods  Patients were randomized to receive either an aggressive infusion of NS or LR. The infusion was started at a rate of 3 mL/kg/hr and continued throughout the ERCP procedure. A 20 mL/kg bolus was given at the end of the procedure, then continued at a rate of 3 mL/kg/hr. Results  A total of 136 patients were included in our analysis. The incidence of PEP was 4 % (3/72 patients) in the LR group versus 11 % (7/64 patients) in the NS group resulting in a relative risk (RR) of 0.38 (95 % confidence interval [CI] 0.10 to 1.42; P  = 0.19). The relative risk reduction (RRR) was 0.62 (95 % CI –0.41 to 0.90) along with an absolute risk reduction (ARR) of 0.07 (95 % CI –0.025 to 0.17) and an number needed to treat of 15 (95 % CI –41 to 6). Conclusions  To our knowledge, this is the first study comparing aggressive IV NS to aggressive IV LR in high-risk patients. The incidence of PEP was lower in the group receiving an aggressive LR infusion (4 %) compared to NS infusion (11 %). However, the difference was not statistically significant likely due to poor accrual thereby impacting the power of the study. Georg Thieme Verlag KG 2022-07-15 /pmc/articles/PMC9286764/ /pubmed/35845031 http://dx.doi.org/10.1055/a-1834-6568 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Patel, Rupal
Bertran-Rodriguez, Carlos
Kumar, Ambuj
Brady, Patrick
Gomez-Esquivel, Rene
Changela, Kinesh
Niknam, Negar
Taunk, Pushpak
Efficacy of aggressive hydration with normal saline versus lactated Ringer’s solution for the prevention of post-ERCP pancreatitis in high-risk patients: a randomized controlled trial
title Efficacy of aggressive hydration with normal saline versus lactated Ringer’s solution for the prevention of post-ERCP pancreatitis in high-risk patients: a randomized controlled trial
title_full Efficacy of aggressive hydration with normal saline versus lactated Ringer’s solution for the prevention of post-ERCP pancreatitis in high-risk patients: a randomized controlled trial
title_fullStr Efficacy of aggressive hydration with normal saline versus lactated Ringer’s solution for the prevention of post-ERCP pancreatitis in high-risk patients: a randomized controlled trial
title_full_unstemmed Efficacy of aggressive hydration with normal saline versus lactated Ringer’s solution for the prevention of post-ERCP pancreatitis in high-risk patients: a randomized controlled trial
title_short Efficacy of aggressive hydration with normal saline versus lactated Ringer’s solution for the prevention of post-ERCP pancreatitis in high-risk patients: a randomized controlled trial
title_sort efficacy of aggressive hydration with normal saline versus lactated ringer’s solution for the prevention of post-ercp pancreatitis in high-risk patients: a randomized controlled trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286764/
https://www.ncbi.nlm.nih.gov/pubmed/35845031
http://dx.doi.org/10.1055/a-1834-6568
work_keys_str_mv AT patelrupal efficacyofaggressivehydrationwithnormalsalineversuslactatedringerssolutionforthepreventionofpostercppancreatitisinhighriskpatientsarandomizedcontrolledtrial
AT bertranrodriguezcarlos efficacyofaggressivehydrationwithnormalsalineversuslactatedringerssolutionforthepreventionofpostercppancreatitisinhighriskpatientsarandomizedcontrolledtrial
AT kumarambuj efficacyofaggressivehydrationwithnormalsalineversuslactatedringerssolutionforthepreventionofpostercppancreatitisinhighriskpatientsarandomizedcontrolledtrial
AT bradypatrick efficacyofaggressivehydrationwithnormalsalineversuslactatedringerssolutionforthepreventionofpostercppancreatitisinhighriskpatientsarandomizedcontrolledtrial
AT gomezesquivelrene efficacyofaggressivehydrationwithnormalsalineversuslactatedringerssolutionforthepreventionofpostercppancreatitisinhighriskpatientsarandomizedcontrolledtrial
AT changelakinesh efficacyofaggressivehydrationwithnormalsalineversuslactatedringerssolutionforthepreventionofpostercppancreatitisinhighriskpatientsarandomizedcontrolledtrial
AT niknamnegar efficacyofaggressivehydrationwithnormalsalineversuslactatedringerssolutionforthepreventionofpostercppancreatitisinhighriskpatientsarandomizedcontrolledtrial
AT taunkpushpak efficacyofaggressivehydrationwithnormalsalineversuslactatedringerssolutionforthepreventionofpostercppancreatitisinhighriskpatientsarandomizedcontrolledtrial